Actelion is initiating Phase III clinical development of the novel antibiotic cadazolid in patients suffering from Clostridium difficile associated diarrhea
Actelion Pharmaceuticals Ltd /
Actelion is initiating Phase III clinical development of the novel antibiotic
cadazolid in patients suffering from Clostridium difficile associated diarrhea
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 10 September 2013 - Actelion (SIX: ATLN)
announced today that it will initiate a Phase III clinical development program
to assess the efficacy and safety of cadazolid in patients with Clostridium
difficile-associated diarrhea (CDAD).
ABOUT THE PHASE III PROGRAM
The Phase III program consists of two identical multi-center, randomized,
double-blind studies comparing the efficacy and safety of cadazolid, (250 mg
administered orally twice daily for 10 days) versus vancomycin, (125 mg
administered orally four times daily for 10 days) in subjects with Clostridium
difficile-associated diarrhea (CDAD).
The program is designed to determine whether the clinical response after
administration of cadazolid is non-inferior to vancomycin in patients with CDAD,
and whether administration of cadazolid is superior to vancomycin in the
sustained clinical response.
The program is expected to enroll more than 1'250 patients worldwide, and is
planned to commence enrollment in the fourth quarter of 2013.
Dr. Dale Gerding, Professor of Medicine at Loyola University Chicago Stritch
School of Medicine, Maywood, IL, Research Physician at Hines, VA Hospital,
Hines, IL and Chairman of the cadazolid Steering Committee, commented: "The
results from the exploratory Phase II study indicate that cadazolid was
numerically similar to, or better than vancomycin on CDAD clinical cure rates as
well as sustained cure rates. These results support initiating the Phase III
program in a larger population, including patients with CDAD due to epidemic
strains."
Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "The
cadazolid Phase III program will address the essential clinical and commercial
requirements for a novel CDAD therapy to be successful, with a focus on making a
meaningful difference for patients. Evidence of a superior sustained cure
compared to vancomycin, including in hypervirulent strains, would go a long way
to meeting the most pressing current medical need. The promising profile of
cadazolid underlines Actelion's commitment to finding new classes of antibiotics
which have a reduced risk of developing resistance."
The results of these Phase III studies are expected to form the basis for
regulatory submissions for marketing approval throughout the world.
CADAZOLID DATA AT ICAAC 2013
Data on cadazolid are currently being presented at the 53rd Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013), in Denver, CO:
Prof. Dale N Gerding, Loyola University, Maywood, Illinois, USA, will present a
poster (K-168) on the "Susceptibility and typing of Clostridium difficile (CD)
isolates from a phase 2 study of the novel antibiotic, cadazolid (CDZ), in CD-
Associated Diarrhea (CDAD)" during the Poster Session 018: Clostridium
difficile. Tuesday, September 10, 2013 12:00 - 2:00 PM
Dr. Alison Mackie, Actelion Pharmaceuticals Ltd, will present a poster (A-008)
on the "Cadazolid, a Novel Potent Antibiotic against Clostridium Difficile:
Minimal Systemic Cadazolid Exposure in Subjects with Clostridium Difficile
Associated Diarrhea" during the Poster Session 004:
Pharmacokinetics/Pharmacodynamics of New Anti-Infective Agents. Tuesday,
September 10, 2013 12:00 - 2:00 PM
Dr. Rodrigo E Mendes, JMI Laboratories, North Liberty, Iowa, USA, will present a
poster (E-144) on the "Activity of cadazolid against Gram-positive clinical
isolates, including linezolid-resistant subsets with defined resistance
mechanisms" during the Poster Session 016: Antimicrobial Activity against Gram-
Positive Bacteria. Tuesday, September 10, 2013 12:00 - 2:00 PM
###
Notes to the Editor
ABOUT CADAZOLID
The novel antibiotic cadazolid is a strong inhibitor of Clostridium difficile
protein synthesis leading to strong suppression of toxin and spore formation. In
preclinical studies cadazolid showed potent in vitro activity against
Clostridium difficile clinical isolates and in a human gut model of Clostridium
difficile associated diarrhea (CDAD), while having only a very limited impact on
bacteria of the normal gut microflora. In addition, cadazolid demonstrated a low
propensity for resistance development.
Cadazolid absorption is negligible resulting in high gut lumen concentrations
and low systemic exposure, even in severe cases of CDAD where the gut wall can
be severely damaged and permeability to drugs potentially increased. The
observed preclinical and clinical pharmacology and safety profiles of cadazolid
supported the further clinical development.
ABOUT CADAZOLID IN PHASE II INVESTIGATION
Cadazolid was studied in a Phase II multi-center, double-blind, randomized,
active reference, parallel group, therapeutic exploratory study. The study
evaluated the efficacy, safety and tolerability of a 10-day, twice daily oral
administration of 3 doses (250 mg, 500 mg or 1,000 mg b.i.d.) of cadazolid in
subjects with Clostridium difficile associated diarrhea (CDAD). As the current
standard of care for CDAD, oral vancomycin (125 mg qid for 10 days) was used as
the active reference. The study was completed in December of 2012, after having
enrolled 84 subjects with mild to severe CDAD.
The results of the Phase II study indicate that the effect of all doses of
cadazolid were numerically similar to, or better than vancomycin on key
endpoints including CDAD clinical cure rates as well as sustained cure rates.
Clinical cure rate was defined as the resolution of diarrhea and no further need
for CDAD therapy at test-of-cure 24 to 72 hours after the last dose of
treatment, while sustained cure rate was defined as clinical cure with no
recurrence of CDAD up to 4 weeks post-treatment. Recurrence rates were
numerically lower for all doses of cadazolid as compared to vancomycin.
Cadazolid was safe and well tolerated, at present no safety signals have been
identified.
ABOUT CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacterium
that is the leading cause of nosocomial diarrhea. Clostridium difficile
associated diarrhea (CDAD or CDI for Clostridium difficile infection) can be a
severe and life-threatening disease and results from the overgrowth in the colon
of toxigenic strains of Clostridium difficile, generally during or after therapy
with broad-spectrum antibiotics. CDAD is a major healthcare problem and a
leading cause of morbidity in elderly hospitalized patients. The frequency and
severity of CDAD in the western world has increased in recent years, and new
hypervirulent and epidemic strains of Clostridium difficile have been discovered
that are characterized by overproduction of toxins and other virulence factors,
and by acquired resistance to fluoroquinolones such as moxifloxacin.
Current antibiotic therapy for CDAD includes vancomycin and metronidazole. While
clinical cure rates are generally 85-90%, recurrences rates of 15-30 % with
either drug are problematic as Clostridium difficile produces spores that are
resistant to antibiotic treatment and routine disinfection. Spores surviving in
the gut of patients and/or in the hospital environment may play a major role in
re-infection and recurrence of CDAD after antibiotic treatment. Vancomycin and
metronidazole are reported to promote spore formation in vitro at sub-inhibitory
concentrations.
Only one new antibiotic, fidaxomicin, has been approved over the last 30 years
for this indication, and there remains a need for new drugs with improved
properties. In particular, antibiotics that allow effective treatment of
infections caused by hypervirulent strains, with low recurrence rates.
ICAAC ABSTRACTS
Gerding D, Best E, Buitrago M, Cornely O, Hecht D, Nord CE, Sambol S, Talbot G,
Wilcox M, Charef P, El-Akkad T, Kracker H, Locher HH, Louie T. Susceptibility
and typing of Clostridium difficile (CD) isolates from a phase 2 study of the
novel antibiotic, cadazolid (CDZ), in CD-Associated Diarrhea (CDAD). Poster (K-
168) presented at the 53rd Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), 10-13 September 2013, Denver, CO.
Mackie AE, Desnica B, Nicolas LB, Louie T, Dingemanse J. Cadazolid, a Novel
Potent Antibiotic against Clostridium Difficile: Minimal Systemic Cadazolid
Exposure in Subjects with Clostridium Difficile Associated Diarrhea. Poster (A-
008) presented at the 53rd Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), 10-13 September 2013, Denver, CO.
Mendes RE, Rhomberg PR, Locher HH, Jones RN. Activity of cadazolid against Gram-
positive clinical isolates, including linezolid-resistant subsets with defined
resistance mechanisms. Poster (E-144) presented at the 53rd Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September
2013, Denver, CO.
References
1. Louie T, Buitrago M, Cornely O, Kracker H, Rangaraju M, Charef P.
Multicentre, double-blind, randomised, phase 2 study evaluating the novel
antibiotic, cadazolid, in subjects with Clostridium difficile-associated
diarrhoea. Late-breaker poster (LB-2956) presented at the 23rd European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27-30
April 2013, Berlin, Germany.
2. Rashid M-U, Martinez Lozano H, Weintraub A, Nord CE. Activity of cadazolid
against clinical isolates of Clostridium difficile. Oral presentation at the
23rd European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), 27-30 April 2013, Berlin, Germany.
3. Caspers P, Ritz D, Locher H, Bruyere T, Schroeder S, Pfaff P, Knezevic A,
Dos Santos M, Hubschwerlen C, Keck W. Cadazolid, a new quinolonyl-
oxazolidinone antibiotic with potent activity against Clostridium difficile
inhibits protein synthesis also in linezolid-resistant strains. Poster (P-
1658) presented at the 23rd European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID), 27-30 April 2013, Berlin, Germany.
4. Seiler P, Enderlin M, Chen X, Pfaff P, Boehme M, Locher HH, Fournier E,
Klenik A, Clozel M, Kelly CP, Keck W. Activity of Cadazolid in Animal
Models of Clostridium difficile Infection. Poster (P-1657) presented at the
23rd European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), 27-30 April 2013, Berlin, Germany.
5. Baldoni D, Gutierrez M, Timmer W, Dingemanse J. Cadazolid, a novel
antibiotic with potent activity against Clostridium difficile: safety,
tolerability, and pharmacokinetics in healthy subjects following single and
multiple oral doses. Poster (A-1273) presented at the 52nd Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 9-12 September
2012, San Francisco.
6. Baines SD, Crowther GS, Todhunter SL, Freeman J, Wilcox MH. In vitro
activity of cadazolid (ACT-179811) against Clostridium difficile and in an
in vitro gut model of C. difficile infection. Poster (B-662) presented at
the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC), 9-12 September 2012, San Francisco.
7. Hecht DW, Osmolski JR, Checknis A, Sambol S, Gerding DN. In vitro activity
of cadazolid against 209 toxigenic isolates of Clostridium difficile. Poster
(E-808) presented at the 52nd Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), 9-12 September 2012, San Francisco.
8. Locher HH, Pfaff P, Schroeder S, Specklin JL, Hubschwerlen C, Keck W.
Cadazolid, a new quinolonyl oxazolidinone with potent activity against
Clostridium difficile: in vitro antibacterial activity and propensity for
resistance development. Poster (C1-1346) presented at the 52nd Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 9-12 September
2012, San Francisco.
9. Locher HH, Ritz D, Schroeder S, Pfaff P, Knezevic A, Hubschwerlen, C, Keck
W. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic: mode of action
and effect on Clostridium difficile toxin and spore formation. Poster (C1-
1347) presented at the 52nd Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC), 9-12 September 2012, San Francisco.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Press Release PDF:
http://hugin.info/131801/R/1728396/577195.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1728396]